Ann Arbor life sciences company Accuri Cytometers landed a $13 million infusion of cash to further expand its marketing and sales efforts. The company completed the Series C financing July 8. Fidelity Biosciences and Flagship Ventures led the effort and current investors including Baird Venture Partners and Arboretum Ventures also participated. Accuri will use the proceeds primarily to expand commercialization of the its C6 Flow Cytometer System. Used by biomedical researchers, the company said its product costs one-third the price of the market leader.("The product) was just released first quarter of 2008 and we're getting great reception in the marketplace," said Accuri CEO Jennifer Baird "We're adding staff, adding customers and this will enable us to continue that and meet customer demand which has been higher than hoped for." Staffing has risen from 13 last year to more than 35 now and Accuri is adding new people every month, Baird said.